SynthesisFrontiers in oncology2026
PSMA PET-guided intensification of postprostatectomy salvage radiotherapy for prostate cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate-specific membrane antigen (PSMA) PET is used to guide postprostatectomy salvage radiotherapy (SRT) and enable intensification through dose escalation and target modification. The oncologic benefit and safety profile of PSMA PET-guided intensification remain uncertain. We aimed to synthesize comparative and single-arm evidence on oncologic outcomes and toxicity of PSMA PET-guided intensification of postprostatectomy SRT. Methods: We performed a systematic review and meta-analysis following PRISMA 2020 guidelines. PubMed, Web of Science, Scopus, Embase and Cochrane Library were searched from inception to 26 December 2025. Comparative and single-arm studies evaluating PSMA PET-guided intensification of postprostatectomy SRT were included. We included clinical studies using PSMA PET/CT or PET/MRI to guide radiotherapy intensification and excluded preclinical studies and non-original reports. Primary outcomes were failure-free survival (FFS) and biochemical recurrence-free survival (bRFS). Secondary outcomes included metastasis- and survival-related endpoints, treatment escalation, and toxicity. Meta-analysis was conducted only when sufficient comparative data were available. Hazard ratios were pooled in RevMan 5.4.1 using fixed- or random-effects models according to heterogeneity. Risk of bias was assessed with the Newcastle-Ottawa Scale. Statistical significance was set at two-sided P<0.05. Results: Fifteen studies met inclusion criteria, including five comparative and ten single-arm studies. Two studies reported FFS-type endpoints; because only two studies were available and endpoint definitions differed substantially, these findings were summarized descriptively. Four comparative studies involving 692 patients contributed to bRFS meta-analysis. PSMA PET-guided SRT showed numerically improved bRFS versus standard SRT, but the difference was not statistically significant (pooled HR 0.61, 95% CI 0.33-1.13; P = 0.12; I²=55%). Other secondary oncologic outcomes were variably reported with limited events and were synthesized descriptively. Severe genitourinary or gastrointestinal toxicity was uncommon, and some studies suggested delayed treatment escalation. Conclusions: PSMA PET-guided intensification of postprostatectomy SRT may improve biochemical control without an increase in severe toxicity; however, a statistically significant bRFS benefit was not demonstrated and evidence for other oncologic outcomes remains limited. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261277044.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.